← Leaderboards
Thiago Bruder
Augusta University
$2,009,505
Attributed
$2,009,505
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $570.3K · FY2018–25$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,009,505 · 3
By mechanism
R01$1,045,238 · 1
R00$733,255 · 1
K99$231,012 · 1
Top collaborators
No co-investigators on record.
Most similar at Augusta University
Same institution · by research overlap
- Eric J Belin De Chantemele$9,748,233
- Aaron James Polichnowski$1,763,750
- Jennifer C Sullivan$9,781,431
- Weiqin Chen$5,046,649
- David J Fulton$11,867,025
Others in their field
Other Emerging Leaders on “Vasodilation”
- Peter J Leary · University Of Washington$5,643,326
- Fabrice Dabertrand · University Of Colorado Denver$4,336,800
- Matthew A Nystoriak · University Of Louisville$4,288,754
- Suman Srinivasa · Massachusetts General Hospital$4,239,550
- Andrew Justin Bryant · University Of Florida$4,040,313
- Pankaj Arora · University Of Alabama At Birmingham$3,911,224
Research focus
VasodilationEndotheliumExperimental StudyVascular DiseasesNew Therapeutic TargetBiological AvailabilityEndothelial DysfunctionEnzymesMouse ModelReactive Oxygen SpeciesCardiovascular DiseasesBlood VesselsMolecularMediatingCardiovascular SystemEndothelial CellsCoronary Heart DiseaseAttenuatedDiabetes MellitusAtherosclerosisAntiretroviral TherapyCongenital DisordersDyslipidemiasCell Growth
Grant awards (7)
Molecular mechanisms of progranulin as a regulator of endothelial biology and blood pressure control$474,975
R01 · FY2025 · HL · contact PI
Molecular mechanisms of progranulin as a regulator of endothelial biology and blood pressure control$570,263
R01 · FY2024 · HL · contact PI
Leptin, a therapeutic avenue for the treatment of vascular disease, focus on congenital and antiretroviral therapy-associated lipodystrophies$239,791
R00 · FY2021 · HL · contact PI
Leptin, a therapeutic avenue for the treatment of vascular disease, focus on congenital and antiretroviral therapy-associated lipodystrophies$244,464
R00 · FY2020 · HL · contact PI
Leptin, a therapeutic avenue for the treatment of vascular disease, focus on congenital and antiretroviral therapy-associated lipodystrophies$249,000
R00 · FY2019 · HL · contact PI
Leptin, a therapeutic avenue for the treatment of vascular disease, focus on congenital and antiretroviral therapy-associated lipodystrophies$115,506
K99 · FY2019 · HL · contact PI
Leptin, a therapeutic avenue for the treatment of vascular disease, focus on congenital and antiretroviral therapy-associated lipodystrophies$115,506
K99 · FY2018 · HL · contact PI